A Phase 1/2 interventional study of GEN1160 in Renal Cell Carcinoma, Nasopharyngeal Carcinoma and Non Hodgkin Lymphoma, sponsored by Genmab. Terminated at 17 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Genmab · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,144 studies in Carcinoma, Renal Cell with a site in United States — 154 open to participants now, 278 under way, 26 of them phase 3. Carcinoma, Renal Cell · United States.
Among the 1,144 studies in Carcinoma, Renal Cell with a site in United States, this one is the 474th largest by enrollment of the 1,010 interventional ones that give a count, is one of 52 that started in 2023, is one of 147 in phase 1/2, and was the 986th registered.
2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.
Browse Carcinoma, Renal Cell studies →154 of the 1,144 studies in Carcinoma, Renal Cell with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
University of Oklahoma · Sites in United States
Ages 18–100 · Men only
Roswell Park Cancer Institute · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,144 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 489 · Phase 2 531 · Phase 3 74 · Phase 4 10
First in 1990; this study’s year is marked. 52 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is close to the median of 43 across 1,569 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 40 across the 1,010 interventional studies, 100 across the 87 observational. Of the 795 that completed or were terminated, 338 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
468 of 1,144 have an industry lead sponsor. The 10 most frequent:
Genmab is the lead sponsor of 72 studies on the registry; 15 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 14 (61%) have results posted.
Genmab has 3 studies filed under Carcinoma, Renal Cell — fewer than ten, so there is no comparison to draw.
97 of the studies in Carcinoma, Renal Cell with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT05678673Phase 3ExelixisStudy of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | 2026-12-15 |
| NCT03592472Phase 3Xynomic Pharmaceuticals, Inc.A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) | 2026-12-30 |
| NCT03873402Phase 3Bristol-Myers SquibbA Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer | 2027-03-11 |
| NCT05863351Phase 3ECOG-ACRIN Cancer Research GroupFocused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study | 2027-08-31 |
Add all 97 to your calendar (.ics) → With an account.
Among the 1,144 studies in Carcinoma, Renal Cell with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Brief Summary:
This study will test the safety, including side effects, and determine the characteristics of a drug called GEN1160 (PRO1160) in participants with solid tumors and blood cancers.
Participants will have cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable) or relapsed or refractory to prior treatments.
This Phase 1/2 study will have three parts. The dose escalation part of the study will find out how much and how frequently GEN1160 should be given to participants. The expansion Part A and expansion Part B will use the dose and schedule found in the dose escalation part to find out how safe GEN1160 is and if it works to treat the diseases under study. The diseases under study will be Renal Cell Carcinoma (RCC), Nasopharyngeal Carcinoma (NPC) and Non-Hodgkin Lymphoma (NHL) in Escalation and diffuse large B-cell lymphoma (DLBCL) in expansion Part A and Part B.
This is a Phase 1/2 study of GEN1160, a CD70 targeted antibody-drug conjugate, to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of GEN1160 in participants with selected locally advanced /or metastatic solid and hematologic malignancies, including RCC, NPC and NHL. This study consists of 3 parts, Dose Escalation, Expansion Part A and Expansion Part B.
Dose escalation may evaluate up to 5 dose levels of GEN1160 on Day 1 of a 21 day cycle by intravenous (IV) infusion.
Expansion will be initiated at a dose level based on a comprehensive analysis of safety, tolerability, clinical PK, pharmacodynamics (PD) and activity data from the dose escalation. Expansion will be conducted in 1 cohort of up to 10 participants (expansion Part A) and 2 further cohorts (expansion Part B), each with up to 25 participants per cohort.
Participants will continue to receive study treatment until the first instance of disease progression, unacceptable toxicity, investigator decision, consent withdrawal, study termination by the Sponsor, initiation of non-GEN1160 anticancer therapy, participant noncompliance, pregnancy, or death.
Dose Escalation: Key Inclusion Criteria:
All participants must have confirmed diagnosis of one of the following tumor types:
Participants must have relapsed or refractory disease following prior systemic therapies known to confer clinical benefit. At minimum, participants should have received the following therapies (unless deemed ineligible, refused by the participant, or not available in the region):
at baseline:
Dose Escalation Key Exclusion Criteria:
Expansion: Key Inclusion Criteria:
Has measurable disease according to the 2014 Lugano criteria (Cheson et al., 2014):
Expansion: Key Exclusion Criteria:
Has been exposed to any of the following prior therapies within the specified timeframes:
Has cardiac disease, including:
Note: Other protocol-defined Inclusion and Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GEN1160 monotherapy in escalating doses in the dose escalation part and at the recommended phase 2 dose in the expansion parts.
Biological: GEN1160
IV infusion of GEN1160
Also known as: PRO1160
Dose Escalation: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a participant or clinical trial participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. TEAEs were events that occurred during treatment or AEs that started before Cycle 1 Day 1 and worsened during the on-treatment period. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Up to approximately 2 years, 7 months
Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLTs)
A DLT was defined as any of the following during the DLT evaluation period if considered not clearly and incontrovertibly due to underlying disease/extraneous causes by the investigator or the sponsor: death not clearly due to underlying disease or extraneous causes, ≥ Grade 3 non-hematologic toxicity (with exceptions per protocol), the abnormality met the definition of drug-induced liver injury (DILI), Grade 4 anemia or Grade 3 anemia lasting \> 7 days (transfusions permitted), Grade 4 neutropenia lasting \> 7 days, Grade 4 thrombocytopenia lasting \> 7 days, or ≥ Grade 3 thrombocytopenia with clinically significant bleeding, ≥ Grade 3 febrile neutropenia (absolute neutrophil count \[ANC\] \< 1000/microliters (µL) with a single oral temperature measurement of ≥ 38.3 centigrade (ºC) (101Fahrenheit \[ºF\]) or a temperature of ≥ 38ºC (100.4ºF) sustained over a 1-hour period), dose delay ≥ 14 days due to toxicity that is not clearly related to the underlying disease or extraneous causes.
Time frame: 28 days
Dose Escalation: Objective Response Rate (ORR) As Assessed by Investigator Using Lugano Criteria for NHL Participants and Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 for RCC/NPC Participants
ORR =percentage of participants with best overall response of complete response (CR) or partial response (PR). CR per Lugano:lymph nodes/extralymphatic sites score 1,2,3 with/without residual mass on 5- performance status, target nodes/nodal masses regress to ≤1.5cm in longest diameter, no extralymphatic disease sites/new lesions/non-measured lesion, organ enlargement regressed to normal, no evidence of specified disease in marrow/marrow normal by morphology. CR per RECIST=disappearance of all target lesions/pathological lymph nodes reduction short axis to\<10mm. PR per Lugano:lymph nodes/extralymphatic sites score 4/5 with reduced uptake vs baseline and residual mass of any size,≥50% decrease in sum of product diameters of up to 6 target nodes, no increase in non-measured lesion, spleen length regressed\>50% beyond normal, residual uptake higher than normal marrow but reduced vs baseline. PR per RECIST:≥ 30% decrease in sum of diameters of target lesions. Full details in protocol.
Time frame: Up to approximately 2 years, 7 months
Dose Escalation: Disease Control Rate (DCR)
DCR was defined as the percentage of participants having stable disease (SD) or achieving a PR or CR (DCR = SD + PR + CR).
Time frame: Up to approximately 2 years, 7 months
Dose Escalation: Progression-free Survival (PFS)
PFS was defined as the time from Cycle 1 Day 1 to first documented progressive disease or death due to any cause, whichever occurred earlier.
Time frame: Up to approximately 2 years, 7 months
Dose Escalation: Duration of Objective Response (DOR)
DOR was defined as the time from the first documentation of response (CR or PR) to the date of progressive disease or death, whichever occurred earlier.
Time frame: Up to approximately 2 years, 7 months
Dose Escalation: Peak Plasma Concentration (Cmax) of GEN1160-related Analytes
Serum samples were taken for analysis of GEN1160-related analytes. Related analytes were total antibody, AC-exatecan, and unconjugated-exatecan.
Time frame: Cycle 1 and Cycle 3 (cycles were 21 days)
Dose Escalation: Time to Maximum Concentration (Tmax) of GEN1160-related Analytes
Serum samples were taken for analysis of GEN1160-related analytes. Related analytes were total antibody, AC-exatecan, and unconjugated-exatecan.
Time frame: Cycle 1 and Cycle 3 (cycles were 21 days)
Dose Escalation: Area Under the Curve up to the Last Quantifiable Time-point (AUC0-last) of GEN1160-related Analytes
Serum samples were taken for analysis of GEN1160-related analytes. Related analytes were total antibody, AC-exatecan, and unconjugated-exatecan.
Time frame: Cycle 1 and Cycle 3 (cycles were 21 days)
Dose Escalation: Number of Participants With Antidrug Antibodies (ADA) to GEN1160
Serum samples were taken for analysis of ADAs to GEN1160.
Time frame: Up to approximately 2 years, 7 months
| Milestone | Dose Escalation: GEN1160 Dose Level 1 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 RCC/NPC | Dose Escalation: GEN1160 Dose Level 3 RCC/NPC | Dose Escalation: GEN1160 Dose Level 4 RCC/NPC | Dose Escalation: GEN1160 Dose Level 5 RCC/NPC | Dose Escalation: GEN1160 Dose Level 6 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 NHL | Dose Escalation: GEN1160 Dose Level 3 NHL | Dose Escalation: GEN1160 Dose Level 5 NHL |
|---|---|---|---|---|---|---|---|---|---|
| Started | 1 | 5 | 11 | 3 | 8 | 5 | 3 | 5 | 1 |
| Received at least 1 dose of treatment | 1 | 5 | 11 | 3 | 8 | 5 | 3 | 5 | 1 |
| Completed | 1 | 2 | 0 | 0 | 2 | 2 | 0 | 0 | 0 |
| Not completed | 0 | 3 | 11 | 3 | 6 | 3 | 3 | 5 | 1 |
| Withdrew: Death | 0 | 3 | 5 | 2 | 1 | 1 | 0 | 3 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Clinical disease progression | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Moved to alternative treatment by pi decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 1 | 0 | 2 | 0 | 2 | 1 | 0 |
| Withdrew: Participant refused follow-up for survival | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Participant refused to participate in the follow-up survival period survey | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 4 | 0 | 1 | 0 | 1 | 1 | 0 |
An adverse event (AE) was any untoward medical occurrence in a participant or clinical trial participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. TEAEs were events that occurred during treatment or AEs that started before Cycle 1 Day 1 and worsened during the on-treatment period. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Dose Escalation: GEN1160 Dose Level 1 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 RCC/NPC | Dose Escalation: GEN1160 Dose Level 3 RCC/NPC | Dose Escalation: GEN1160 Dose Level 4 RCC/NPC | Dose Escalation: GEN1160 Dose Level 5 RCC/NPC | Dose Escalation: GEN1160 Dose Level 6 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 NHL | Dose Escalation: GEN1160 Dose Level 3 NHL | Dose Escalation: GEN1160 Dose Level 5 NHL |
|---|---|---|---|---|---|---|---|---|---|
| Dose Escalation: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 1 | 5 | 11 | 3 | 8 | 5 | 3 | 5 | 1 |
A DLT was defined as any of the following during the DLT evaluation period if considered not clearly and incontrovertibly due to underlying disease/extraneous causes by the investigator or the sponsor: death not clearly due to underlying disease or extraneous causes, ≥ Grade 3 non-hematologic toxicity (with exceptions per protocol), the abnormality met the definition of drug-induced liver injury (DILI), Grade 4 anemia or Grade 3 anemia lasting \> 7 days (transfusions permitted), Grade 4 neutropenia lasting \> 7 days, Grade 4 thrombocytopenia lasting \> 7 days, or ≥ Grade 3 thrombocytopenia with clinically significant bleeding, ≥ Grade 3 febrile neutropenia (absolute neutrophil count \[ANC\] \< 1000/microliters (µL) with a single oral temperature measurement of ≥ 38.3 centigrade (ºC) (101Fahrenheit \[ºF\]) or a temperature of ≥ 38ºC (100.4ºF) sustained over a 1-hour period), dose delay ≥ 14 days due to toxicity that is not clearly related to the underlying disease or extraneous causes.
| Participants | Dose Escalation: GEN1160 Dose Level 1 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 RCC/NPC | Dose Escalation: GEN1160 Dose Level 3 RCC/NPC | Dose Escalation: GEN1160 Dose Level 4 RCC/NPC | Dose Escalation: GEN1160 Dose Level 5 RCC/NPC | Dose Escalation: GEN1160 Dose Level 6 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 NHL | Dose Escalation: GEN1160 Dose Level 3 NHL | Dose Escalation: GEN1160 Dose Level 5 NHL |
|---|---|---|---|---|---|---|---|---|---|
| Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLTs) | 0 | 0 | 2 | 1 | 1 | 1 | 0 | 0 | 0 |
ORR =percentage of participants with best overall response of complete response (CR) or partial response (PR). CR per Lugano:lymph nodes/extralymphatic sites score 1,2,3 with/without residual mass on 5- performance status, target nodes/nodal masses regress to ≤1.5cm in longest diameter, no extralymphatic disease sites/new lesions/non-measured lesion, organ enlargement regressed to normal, no evidence of specified disease in marrow/marrow normal by morphology. CR per RECIST=disappearance of all target lesions/pathological lymph nodes reduction short axis to\<10mm. PR per Lugano:lymph nodes/extralymphatic sites score 4/5 with reduced uptake vs baseline and residual mass of any size,≥50% decrease in sum of product diameters of up to 6 target nodes, no increase in non-measured lesion, spleen length regressed\>50% beyond normal, residual uptake higher than normal marrow but reduced vs baseline. PR per RECIST:≥ 30% decrease in sum of diameters of target lesions. Full details in protocol.
| percentage of participants | Dose Escalation: GEN1160 Dose Level 1 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 RCC/NPC | Dose Escalation: GEN1160 Dose Level 3 RCC/NPC | Dose Escalation: GEN1160 Dose Level 4 RCC/NPC | Dose Escalation: GEN1160 Dose Level 5 RCC/NPC | Dose Escalation: GEN1160 Dose Level 6 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 NHL | Dose Escalation: GEN1160 Dose Level 3 NHL | Dose Escalation: GEN1160 Dose Level 5 NHL |
|---|---|---|---|---|---|---|---|---|---|
| Dose Escalation: Objective Response Rate (ORR) As Assessed by Investigator Using Lugano Criteria for NHL Participants and Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 for RCC/NPC Participants | 0 (0.0 to 97.5) | 0 (0.0 to 52.2) | 9.1 (0.2 to 41.3) | 0 (0.0 to 84.2) | 12.5 (0.3 to 52.7) | 0 (0.0 to 52.2) | 33.3 (0.8 to 90.6) | 60.0 (14.7 to 94.7) | 100 (2.5 to 100.0) |
DCR was defined as the percentage of participants having stable disease (SD) or achieving a PR or CR (DCR = SD + PR + CR).
| percentage of participants | Dose Escalation: GEN1160 Dose Level 1 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 RCC/NPC | Dose Escalation: GEN1160 Dose Level 3 RCC/NPC | Dose Escalation: GEN1160 Dose Level 4 RCC/NPC | Dose Escalation: GEN1160 Dose Level 5 RCC/NPC | Dose Escalation: GEN1160 Dose Level 6 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 NHL | Dose Escalation: GEN1160 Dose Level 3 NHL | Dose Escalation: GEN1160 Dose Level 5 NHL |
|---|---|---|---|---|---|---|---|---|---|
| Dose Escalation: Disease Control Rate (DCR) | 100 (2.5 to 100.0) | 80.0 (28.4 to 99.5) | 72.7 (39.0 to 94.0) | 50.0 (1.3 to 98.7) | 87.5 (47.3 to 99.7) | 60.0 (14.7 to 94.7) | 33.3 (0.8 to 90.6) | 80.0 (28.4 to 99.5) | 100 (2.5 to 100.0) |
PFS was defined as the time from Cycle 1 Day 1 to first documented progressive disease or death due to any cause, whichever occurred earlier.
| months | Dose Escalation: GEN1160 Dose Level 1 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 RCC/NPC | Dose Escalation: GEN1160 Dose Level 3 RCC/NPC | Dose Escalation: GEN1160 Dose Level 4 RCC/NPC | Dose Escalation: GEN1160 Dose Level 5 RCC/NPC | Dose Escalation: GEN1160 Dose Level 6 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 NHL | Dose Escalation: GEN1160 Dose Level 3 NHL | Dose Escalation: GEN1160 Dose Level 5 NHL |
|---|---|---|---|---|---|---|---|---|---|
| Dose Escalation: Progression-free Survival (PFS) | 2.8 | 4.2 (1.8 to NA) | 5.4 (1.4 to NA) | NA (1.2 to NA) | 4.8 (1.3 to NA) | 2.6 (1.1 to NA) | 1.3 (1.3 to NA) | 4.0 (1.3 to NA) | NA (NA to NA) |
DOR was defined as the time from the first documentation of response (CR or PR) to the date of progressive disease or death, whichever occurred earlier.
| months | Dose Escalation: GEN1160 Dose Level 1 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 RCC/NPC | Dose Escalation: GEN1160 Dose Level 3 RCC/NPC | Dose Escalation: GEN1160 Dose Level 4 RCC/NPC | Dose Escalation: GEN1160 Dose Level 5 RCC/NPC | Dose Escalation: GEN1160 Dose Level 6 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 NHL | Dose Escalation: GEN1160 Dose Level 3 NHL | Dose Escalation: GEN1160 Dose Level 5 NHL |
|---|---|---|---|---|---|---|---|---|---|
| Dose Escalation: Duration of Objective Response (DOR) | — | — | NA | — | 11.0 | — | 9.2 | 1.5 (NA to NA) | NA |
Serum samples were taken for analysis of GEN1160-related analytes. Related analytes were total antibody, AC-exatecan, and unconjugated-exatecan.
| nanograms per milliliter (ng/ml) | Dose Escalation: GEN1160 Dose Level 1 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 RCC/NPC | Dose Escalation: GEN1160 Dose Level 3 RCC/NPC | Dose Escalation: GEN1160 Dose Level 4 RCC/NPC | Dose Escalation: GEN1160 Dose Level 5 RCC/NPC | Dose Escalation: GEN1160 Dose Level 6 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 NHL | Dose Escalation: GEN1160 Dose Level 3 NHL | Dose Escalation: GEN1160 Dose Level 5 NHL |
|---|---|---|---|---|---|---|---|---|---|
| Total Antibody Cycle 1 | 26912.40 | 68798.86 ± 28.3 | 87114.23 ± 22.4 | 90507.21 ± 30.8 | 139695.48 ± 16.4 | 150329.90 ± 12.2 | 66595.65 ± 26.7 | 100934.62 ± 24.0 | 77402.80 |
| Total Antibody Cycle 3 | 40062.80 | 86083.11 ± 31.9 | 87487.78 ± 27.8 | 133915.00 | 101628.03 ± 38.5 | 138101.20 ± 44.4 | 58200.00 | 104881.09 ± 47.9 | 97633.20 |
| AC-exatecan Cycle 1 | 609.0 | 1233.6 ± 9.3 | 1703.4 ± 23.8 | 1683.3 ± 23.6 | 2679.7 ± 16.3 | 3058.1 ± 29.2 | 1276.8 ± 12.1 | 1730.3 ± 24.1 | 1520.0 |
| AC-exatecan Cycle 3 | 704.0 | 1588.2 ± 26.1 | 1562.2 ± 25.3 | 1600.0 | 2351.5 ± 44.2 | 2781.7 ± 37.5 | 1230.0 | 1586.8 ± 19.0 | 1960.0 |
| Unconjugated-exatecan Cycle 1 | 1.500 | 3.821 ± 33.0 | 5.833 ± 46.1 | 9.479 ± 39.6 | 11.128 ± 92.5 | 11.074 ± 32.6 | 5.030 ± 18.3 | 5.399 ± 32.5 | 12.000 |
| Unconjugated-exatecan Cycle 3 | 1.550 | 4.151 ± 72.8 | 5.382 ± 47.3 | 8.060 | 8.428 ± 43.9 | 10.900 ± 38.4 | 4.670 | 2.638 ± 99.6 | 8.970 |
Serum samples were taken for analysis of GEN1160-related analytes. Related analytes were total antibody, AC-exatecan, and unconjugated-exatecan.
| days | Dose Escalation: GEN1160 Dose Level 1 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 RCC/NPC | Dose Escalation: GEN1160 Dose Level 3 RCC/NPC | Dose Escalation: GEN1160 Dose Level 4 RCC/NPC | Dose Escalation: GEN1160 Dose Level 5 RCC/NPC | Dose Escalation: GEN1160 Dose Level 6 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 NHL | Dose Escalation: GEN1160 Dose Level 3 NHL | Dose Escalation: GEN1160 Dose Level 5 NHL |
|---|---|---|---|---|---|---|---|---|---|
| Total Antibody Cycle 1 | 0.033 (0.033 to 0.033) | 0.038 (0.03 to 0.11) | 0.037 (0.03 to 0.12) | 0.036 (0.03 to 0.09) | 0.057 (0.03 to 0.81) | 0.026 (0.02 to 0.04) | 0.092 (0.03 to 0.15) | 0.122 (0.03 to 0.14) | 0.035 (0.035 to 0.035) |
| Total Antibody Cycle 3 | 0.033 (0.033 to 0.033) | 0.064 (0.03 to 0.11) | 0.063 (0.03 to 0.90) | 0.044 (0.044 to 0.044) | 0.039 (0.03 to 0.09) | 0.069 (0.03 to 0.11) | 0.124 (0.124 to 0.124) | 0.118 (0.02 to 0.12) | 0.034 (0.034 to 0.034) |
| AC-exatecan Cycle 1 | 0.033 (0.033 to 0.033) | 0.038 (0.03 to 0.11) | 0.037 (0.03 to 0.12) | 0.036 (0.03 to 0.09) | 0.041 (0.03 to 0.11) | 0.033 (0.02 to 0.11) | 0.072 (0.03 to 0.09) | 0.065 (0.03 to 0.12) | 0.035 (0.035 to 0.035) |
| AC-exatecan Cycle 3 | 0.033 (0.033 to 0.033) | 0.034 (0.03 to 0.04) | 0.033 (0.03 to 0.11) | 0.044 (0.044 to 0.044) | 0.060 (0.03 to 0.13) | 0.034 (0.03 to 0.04) | 0.048 (0.048 to 0.048) | 0.034 (0.02 to 0.05) | 0.102 (0.102 to 0.102) |
| Unconjugated-exatecan Cycle 1 | 1.058 (1.058 to 1.058) | 1.018 (0.90 to 3.01) | 0.966 (0.79 to 1.11) | 1.050 (1.02 to 2.96) | 1.671 (0.81 to 6.90) | 2.103 (0.74 to 4.06) | 1.134 (1.00 to 2.83) | 0.885 (0.84 to 2.99) | 0.728 (0.728 to 0.728) |
| Unconjugated-exatecan Cycle 3 | 1.023 (1.023 to 1.023) | 1.538 (0.92 to 3.05) | 0.925 (0.74 to 2.76) | 0.958 (0.958 to 0.958) | 1.015 (0.99 to 2.00) | 1.942 (0.98 to 2.91) | 3.690 (3.690 to 3.690) | 0.832 (0.12 to 8.87) | 0.863 (0.863 to 0.863) |
Serum samples were taken for analysis of GEN1160-related analytes. Related analytes were total antibody, AC-exatecan, and unconjugated-exatecan.
| day*ng/mL | Dose Escalation: GEN1160 Dose Level 1 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 RCC/NPC | Dose Escalation: GEN1160 Dose Level 3 RCC/NPC | Dose Escalation: GEN1160 Dose Level 4 RCC/NPC | Dose Escalation: GEN1160 Dose Level 5 RCC/NPC | Dose Escalation: GEN1160 Dose Level 6 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 NHL | Dose Escalation: GEN1160 Dose Level 3 NHL | Dose Escalation: GEN1160 Dose Level 5 NHL |
|---|---|---|---|---|---|---|---|---|---|
| Total Antibody Cycle 1 | 76755.338 | 232276.559 ± 17.7 | 334061.153 ± 33.0 | 269213.463 ± 21.3 | 550056.322 ± 27.7 | 698705.608 ± 23.2 | 271275.855 ± 26.0 | 456216.535 ± 23.5 | 351585.995 |
| Total Antibody Cycle 3 | 102735.629 | 362233.965 ± 32.5 | 352217.495 ± 42.9 | 193252.651 | 481017.681 ± 38.7 | 680713.940 ± 45.3 | 427201.677 | 586698.427 ± 58.2 | 509667.449 |
| AC-exatecan Cycle 1 | 1506.758 | 3604.888 ± 22.4 | 5272.914 ± 27.6 | 4608.437 ± 5.6 | 9105.011 ± 32.9 | 12920.183 ± 21.3 | 4451.604 ± 0.9 | 6174.833 ± 7.4 | 5977.469 |
| AC-exatecan Cycle 3 | 1797.699 | 5106.784 ± 32.8 | 4988.139 ± 40.7 | 3530.893 | 7995.783 ± 33.5 | 12829.939 ± 47.5 | 5350.258 | 7433.467 ± 37.0 | 7756.499 |
| Unconjugated-exatecan Cycle 1 | 8.088 | 23.281 ± 35.4 | 34.721 ± 44.5 | 45.652 ± 45.9 | 74.917 ± 43.8 | 95.424 ± 37.3 | 36.611 ± 45.6 | 31.710 ± 22.8 | 47.218 |
| Unconjugated-exatecan Cycle 3 | 8.485 | 25.096 ± 65.0 | 31.692 ± 32.8 | 28.453 | 49.378 ± 33.1 | 99.175 ± 37.7 | 33.814 | 24.595 ± 89.9 | 39.469 |
Serum samples were taken for analysis of ADAs to GEN1160.
| Participants | Dose Escalation: GEN1160 Dose Level 1 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 RCC/NPC | Dose Escalation: GEN1160 Dose Level 3 RCC/NPC | Dose Escalation: GEN1160 Dose Level 4 RCC/NPC | Dose Escalation: GEN1160 Dose Level 5 RCC/NPC | Dose Escalation: GEN1160 Dose Level 6 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 NHL | Dose Escalation: GEN1160 Dose Level 3 NHL | Dose Escalation: GEN1160 Dose Level 5 NHL |
|---|---|---|---|---|---|---|---|---|---|
| Dose Escalation: Number of Participants With Antidrug Antibodies (ADA) to GEN1160 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over Up to approximately 2 years, 7 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Escalation: GEN1160 Dose Level 1 RCC/NPC | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Dose Escalation: GEN1160 Dose Level 2 RCC/NPC | 3/5 (60%) | 2/5 (40%) | 5/5 (100%) |
| Dose Escalation: GEN1160 Dose Level 3 RCC/NPC | 6/11 (54.5%) | 5/11 (45.5%) | 11/11 (100%) |
| Dose Escalation: GEN1160 Dose Level 4 RCC/NPC | 2/3 (66.7%) | 1/3 (33.3%) | 3/3 (100%) |
| Dose Escalation: GEN1160 Dose Level 5 RCC/NPC | 1/8 (12.5%) | 4/8 (50%) | 8/8 (100%) |
| Dose Escalation: GEN1160 Dose Level 6 RCC/NPC | 1/5 (20%) | 5/5 (100%) | 4/5 (80%) |
| Dose Escalation: GEN1160 Dose Level 2 NHL | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Dose Escalation: GEN1160 Dose Level 3 NHL | 3/5 (60%) | 0/5 (0%) | 5/5 (100%) |
| Dose Escalation: GEN1160 Dose Level 5 NHL | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Event | Dose Escalation: GEN1160 Dose Level 1 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 RCC/NPC | Dose Escalation: GEN1160 Dose Level 3 RCC/NPC | Dose Escalation: GEN1160 Dose Level 4 RCC/NPC | Dose Escalation: GEN1160 Dose Level 5 RCC/NPC | Dose Escalation: GEN1160 Dose Level 6 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 NHL | Dose Escalation: GEN1160 Dose Level 3 NHL | Dose Escalation: GEN1160 Dose Level 5 NHL |
|---|---|---|---|---|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 0/1 | 0/5 | 1/11 | 0/3 | 0/8 | 3/5 | 0/3 | 0/5 | 0/1 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/1 | 0/5 | 1/11 | 0/3 | 0/8 | 2/5 | 0/3 | 0/5 | 0/1 |
| HyponatraemiaMetabolism and nutrition disorders | 0/1 | 0/5 | 0/11 | 1/3 | 0/8 | 0/5 | 0/3 | 0/5 | 0/1 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/1 | 0/5 | 0/11 | 0/3 | 2/8 | 0/5 | 0/3 | 0/5 | 0/1 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/1 | 0/5 | 0/11 | 0/3 | 0/8 | 1/5 | 0/3 | 0/5 | 0/1 |
| DiarrhoeaGastrointestinal disorders | 0/1 | 0/5 | 0/11 | 0/3 | 0/8 | 1/5 | 0/3 | 0/5 | 0/1 |
| Humerus fractureInjury, poisoning and procedural complications | 0/1 | 0/5 | 0/11 | 0/3 | 0/8 | 1/5 | 0/3 | 0/5 | 0/1 |
| FatigueGeneral disorders | 0/1 | 0/5 | 1/11 | 0/3 | 0/8 | 1/5 | 0/3 | 0/5 | 0/1 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 0/1 | 0/5 | 0/11 | 0/3 | 0/8 | 1/5 | 0/3 | 0/5 | 0/1 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/1 | 0/5 | 0/11 | 0/3 | 0/8 | 1/5 | 0/3 | 0/5 | 0/1 |
| Event | Dose Escalation: GEN1160 Dose Level 1 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 RCC/NPC | Dose Escalation: GEN1160 Dose Level 3 RCC/NPC | Dose Escalation: GEN1160 Dose Level 4 RCC/NPC | Dose Escalation: GEN1160 Dose Level 5 RCC/NPC | Dose Escalation: GEN1160 Dose Level 6 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 NHL | Dose Escalation: GEN1160 Dose Level 3 NHL | Dose Escalation: GEN1160 Dose Level 5 NHL |
|---|---|---|---|---|---|---|---|---|---|
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/1 | 1/5 | 0/11 | 0/3 | 0/8 | 0/5 | 0/3 | 0/5 | 1/1 |
| DiarrhoeaGastrointestinal disorders | 0/1 | 1/5 | 3/11 | 1/3 | 3/8 | 1/5 | 0/3 | 3/5 | 1/1 |
| Lymphocyte count increasedInvestigations | 0/1 | 0/5 | 0/11 | 0/3 | 0/8 | 0/5 | 0/3 | 0/5 | 1/1 |
| ProteinuriaRenal and urinary disorders | 0/1 | 1/5 | 3/11 | 0/3 | 0/8 | 0/5 | 0/3 | 0/5 | 1/1 |
| White blood cell count decreasedInvestigations | 0/1 | 2/5 | 3/11 | 1/3 | 1/8 | 0/5 | 1/3 | 4/5 | 1/1 |
| NeutropeniaBlood and lymphatic system disorders | 0/1 | 2/5 | 2/11 | 0/3 | 4/8 | 2/5 | 1/3 | 5/5 | 1/1 |
| HyponatraemiaMetabolism and nutrition disorders | 1/1 | 2/5 | 3/11 | 1/3 | 0/8 | 2/5 | 1/3 | 0/5 | 1/1 |
| NauseaGastrointestinal disorders | 0/1 | 3/5 | 9/11 | 1/3 | 7/8 | 3/5 | 1/3 | 1/5 | 1/1 |
| AnaemiaBlood and lymphatic system disorders | 0/1 | 3/5 | 5/11 | 2/3 | 3/8 | 2/5 | 2/3 | 3/5 | 1/1 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/1 | 1/5 | 2/11 | 0/3 | 4/8 | 1/5 | 1/3 | 4/5 | 1/1 |
Full Analysis Set (FAS) included all participants who received any amount of GEN1160. Participants were analyzed according to actual treatment (dose level).
| Age, Categorical(Participants) | Dose Escalation: GEN1160 Dose Level 1 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 RCC/NPC | Dose Escalation: GEN1160 Dose Level 3 RCC/NPC | Dose Escalation: GEN1160 Dose Level 4 RCC/NPC | Dose Escalation: GEN1160 Dose Level 5 RCC/NPC | Dose Escalation: GEN1160 Dose Level 6 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 NHL | Dose Escalation: GEN1160 Dose Level 3 NHL | Dose Escalation: GEN1160 Dose Level 5 NHL | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 4 | 9 | 1 | 7 | 3 | 1 | 5 | 1 | 32 |
| >=65 years | 0 | 1 | 2 | 2 | 1 | 2 | 2 | 0 | 0 | 10 |
| Age, Continuous(years) | Dose Escalation: GEN1160 Dose Level 1 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 RCC/NPC | Dose Escalation: GEN1160 Dose Level 3 RCC/NPC | Dose Escalation: GEN1160 Dose Level 4 RCC/NPC | Dose Escalation: GEN1160 Dose Level 5 RCC/NPC | Dose Escalation: GEN1160 Dose Level 6 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 NHL | Dose Escalation: GEN1160 Dose Level 3 NHL | Dose Escalation: GEN1160 Dose Level 5 NHL | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 64 | 51 ± 16.2 | 53.4 ± 11.3 | 70.3 ± 11.2 | 56.6 ± 11 | 59.8 ± 17.3 | 66 ± 2.6 | 54 ± 6.7 | 55 | 57 ± 12.2 |
| Sex: Female, Male(Participants) | Dose Escalation: GEN1160 Dose Level 1 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 RCC/NPC | Dose Escalation: GEN1160 Dose Level 3 RCC/NPC | Dose Escalation: GEN1160 Dose Level 4 RCC/NPC | Dose Escalation: GEN1160 Dose Level 5 RCC/NPC | Dose Escalation: GEN1160 Dose Level 6 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 NHL | Dose Escalation: GEN1160 Dose Level 3 NHL | Dose Escalation: GEN1160 Dose Level 5 NHL | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 3 | 1 | 1 | 0 | 1 | 2 | 0 | 8 |
| Male | 1 | 5 | 8 | 2 | 7 | 5 | 2 | 3 | 1 | 34 |
| Race/Ethnicity, Customized(Participants) | Dose Escalation: GEN1160 Dose Level 1 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 RCC/NPC | Dose Escalation: GEN1160 Dose Level 3 RCC/NPC | Dose Escalation: GEN1160 Dose Level 4 RCC/NPC | Dose Escalation: GEN1160 Dose Level 5 RCC/NPC | Dose Escalation: GEN1160 Dose Level 6 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 NHL | Dose Escalation: GEN1160 Dose Level 3 NHL | Dose Escalation: GEN1160 Dose Level 5 NHL | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 4 |
| Not Hispanic or Latino | 1 | 5 | 10 | 3 | 8 | 4 | 3 | 4 | 0 | 38 |
| Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Dose Escalation: GEN1160 Dose Level 1 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 RCC/NPC | Dose Escalation: GEN1160 Dose Level 3 RCC/NPC | Dose Escalation: GEN1160 Dose Level 4 RCC/NPC | Dose Escalation: GEN1160 Dose Level 5 RCC/NPC | Dose Escalation: GEN1160 Dose Level 6 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 NHL | Dose Escalation: GEN1160 Dose Level 3 NHL | Dose Escalation: GEN1160 Dose Level 5 NHL | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 2 | 4 | 1 | 2 | 1 | 1 | 4 | 0 | 15 |
| Black or African American | 0 | 0 | 1 | 0 | 1 | 2 | 0 | 0 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 |
| Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 1 | 3 | 6 | 2 | 5 | 2 | 1 | 1 | 0 | 21 |
| Region of Enrollment(Participants) | Dose Escalation: GEN1160 Dose Level 1 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 RCC/NPC | Dose Escalation: GEN1160 Dose Level 3 RCC/NPC | Dose Escalation: GEN1160 Dose Level 4 RCC/NPC | Dose Escalation: GEN1160 Dose Level 5 RCC/NPC | Dose Escalation: GEN1160 Dose Level 6 RCC/NPC | Dose Escalation: GEN1160 Dose Level 2 NHL | Dose Escalation: GEN1160 Dose Level 3 NHL | Dose Escalation: GEN1160 Dose Level 5 NHL | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| China | 0 | 2 | 4 | 1 | 1 | 0 | 1 | 3 | 0 | 12 |
| United States | 1 | 3 | 7 | 2 | 7 | 5 | 2 | 2 | 1 | 30 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2023 to primary completion in Nov 2025, 31 months.
Results were first posted in Nov 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.